北陆药业: 关于控股股东、实际控制人因可转债转股持股比例被动稀释触及1%整数倍的权益变动公告

Core Points - The announcement details a passive dilution of the shareholding percentage of the controlling shareholder and actual controller, Wang Daixue, from 17.08% to 16.92% due to the conversion of convertible bonds into shares, which triggered a change in equity that touched a 1% integer multiple [1][4] - The company issued convertible bonds totaling 500 million yuan, which began trading on December 28, 2020, under the name "Beilu Convertible Bonds" [1][2] - The change in shareholding will not affect the company's governance structure or ongoing operations [1][4] Summary of Equity Change - The equity change occurred due to the conversion of convertible bonds, resulting in a decrease in Wang Daixue's shareholding by 0.16% [3][4] - After the equity change, Wang Daixue holds 85,453,483 shares, representing 16.92% of the total share capital [2][4] - The conversion period for the bonds is from June 11, 2021, to December 2026 [2] Other Matters - The company assures that the change in the controlling shareholder will not impact the stability of control or the governance structure [4][5]